WO2023193730A1 - 一种甲基奥瑞他汀e中间体的制备及纯化方法 - Google Patents

一种甲基奥瑞他汀e中间体的制备及纯化方法 Download PDF

Info

Publication number
WO2023193730A1
WO2023193730A1 PCT/CN2023/086387 CN2023086387W WO2023193730A1 WO 2023193730 A1 WO2023193730 A1 WO 2023193730A1 CN 2023086387 W CN2023086387 W CN 2023086387W WO 2023193730 A1 WO2023193730 A1 WO 2023193730A1
Authority
WO
WIPO (PCT)
Prior art keywords
organic solvent
preparation
compound
methanol
protecting group
Prior art date
Application number
PCT/CN2023/086387
Other languages
English (en)
French (fr)
Inventor
朱梅英
李海涛
梁鑫
李新利
孙晓晴
孙鹏
肖凯
梁晓伟
高金国
Original Assignee
荣昌生物制药(烟台)股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荣昌生物制药(烟台)股份有限公司 filed Critical 荣昌生物制药(烟台)股份有限公司
Priority to CN202380013588.1A priority Critical patent/CN117980291A/zh
Publication of WO2023193730A1 publication Critical patent/WO2023193730A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Definitions

  • the present invention relates to the field of compound synthesis methods, and specifically relates to a preparation and purification method of a methyl auristatin E compound (MMAE) intermediate.
  • MMAE methyl auristatin E compound
  • MMAE Monomethyl Auristatin E, also known as methyl auristatin E
  • MMAE is a fully synthetic derivative of auristatin. It can effectively inhibit mitosis by inhibiting tubulin polymerization and has been widely used.
  • the cytotoxic component i.e. the drug part
  • ADC antibody drug conjugates
  • the more general preparation route of MMAE is as follows, in which compound b involved in step 1 is the main intermediate in the preparation of MMAE.
  • the current preparation method of compound b has problems such as low purity or low yield of the prepared product or a large number of residual impurities.
  • the Chinese patent with publication number CN105968038A discloses a method for preparing dipeptide compound hydrochloride (i.e., compound b). The route is:
  • This patent discloses such a preparation and purification method in Example 8 on page 7 of the specification: after removing the Boc protecting group of Compound A using hydrochloric acid, methyl tert-butyl ether, dioxane, and methyl methyl ether are added in sequence. After using tert-butyl ether, the crude product of compound b was obtained, and then used tetrahydrofuran and Heptane was used for purification to obtain purified compound b with a purity of 99.6%, but the yield was only 82.3%.
  • the dioxane involved in this method is easily oxidized and prone to explosion after oxidation, which brings many dangerous factors to safety production.
  • the present invention provides a new preparation and purification method of methyl auristatin E intermediate.
  • organic reagents to concentrate and remove impurities under reduced pressure, high-purity and low-impurity methyl auristatin E is prepared.
  • Statin E intermediate By using organic reagents to concentrate and remove impurities under reduced pressure, high-purity and low-impurity methyl auristatin E is prepared.
  • Statin E intermediate By using organic reagents to concentrate and remove impurities under reduced pressure, high-purity and low-impurity methyl auristatin E is prepared.
  • Statin E intermediate By using organic reagents to concentrate and remove impurities under reduced pressure, high-purity and low-impurity methyl auristatin E is prepared.
  • the preparation route of the described preparation and purification method is:
  • the R is an amino protecting group
  • the preparation and purification method includes the following steps:
  • step A After the reaction in step A is completed, add an appropriate amount of the first organic solvent to the reaction solution in step A, and concentrate under reduced pressure to obtain concentrate a;
  • step C Add an appropriate amount of the second organic solvent to the concentrate a obtained in step B, and concentrate under reduced pressure to obtain the concentrate b;
  • R can be any amino-protecting group that can remove amino-protection by hydrochloric acid method.
  • the amino protecting group R is a Boc protecting group, Cbz protecting group, Tfa protecting group, Tos protecting group, Trt protecting group, or DMB protecting group, that is, the amino protecting group
  • the structure of R can be selected without limitation from:
  • the first organic solvent is selected from acetonitrile, absolute ethanol, and methanol;
  • the second organic solvent is selected from acetonitrile, absolute ethanol, and methanol;
  • the compound 1 can be selected from the following structures:
  • the structure of compound 1 is:
  • the structure of compound 1 is:
  • the structure of compound 1 is:
  • the structure of compound 1 is:
  • the structure of compound 1 is:
  • the structure of compound 1 is:
  • the step D further includes step D1.
  • the step D1 includes: adding an appropriate amount of a third organic solvent to the concentrate b obtained in step C, stirring and dissolving, to obtain a solution c. ;
  • the third organic solvent is selected from methanol or absolute ethanol.
  • the step D further includes step D2.
  • the step D2 is performed after the step D1.
  • the step D2 includes: adding an appropriate amount of the dissolving liquid c obtained in the step D1.
  • Four organic solvents are filtered, and the filter cake is obtained. After drying, the compound represented by formula (I) is obtained; the fourth organic solvent is selected from n-hexane or methyl tert-butyl ether.
  • the weight-to-volume ratio (g/ml) of compound 1 described in step A and the first organic solvent described in step B is 1:4-15. In some specific embodiments, the weight to volume ratio of compound 1 described in step A and the first organic solvent described in step B is (g/ml) is 1:4 or 1:5 or 1:6 or 1:7 or 1:8 or 1:9 or 1:10 or 1:11 or 1:12 or 1:13 or 1:14 or 1:15 In some specific embodiments, the weight-to-volume ratio of compound 1 described in step A and the first organic solvent described in step B can also be other ratios in the above-mentioned range of 1:4 to 15.
  • the vacuum concentration temperature described in step B is 20-40°C. In some specific embodiments, the vacuum concentration temperature described in step B is 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C °C, 31 °C, 32 °C, 33 °C, 34 °C, 35 °C, 36 °C, 37 °C, 38 °C, 39 °C, or 40 °C; in other specific embodiments, the reduced pressure described in step B The concentration temperature is other temperatures in the range of 20-40°C.
  • the weight-to-volume ratio (g/ml) of compound 1 described in step A and the second organic solvent described in step C is 1:4-15. In some specific embodiments, the weight to volume ratio (g/ml) of compound 1 described in step A and the second organic solvent described in step C is 1:4, 1:5, 1:6, 1 :7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14 or 1:15; in some specific embodiments, the compound described in step A
  • the weight-to-volume ratio between 1 and the second organic solvent described in step C can also be other ratios within the above-mentioned range.
  • the vacuum concentration temperature described in step C is 20-40°C. In some specific embodiments, the vacuum concentration temperature described in step C is 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C °C, 31 °C, 32 °C, 33 °C, 34 °C, 35 °C, 36 °C, 37 °C, 38 °C, 39 °C or 40 °C; in some specific embodiments, the vacuum concentration temperature described in step C Other temperatures within the range of 20-40°C are also possible.
  • the weight-to-volume ratio (g/ml) of compound 1 described in step A and the third organic solvent described in step D1 is 1:2-8.
  • the weight to volume ratio (g/ml) of compound 1 described in step A and the third organic solvent described in step D1 is 1:2, 1:3, 1:4, 1 :5, 1:6, 1:7 or 1:8; in other specific embodiments, the weight to volume ratio of the compound 1 described in step A and the third organic solvent described in step D1 can be the above Other proportions within the stated range.
  • the weight-to-volume ratio (g/ml) of compound 1 described in step A and the fourth organic solvent described in step D2 is 1:10-50. In some specific embodiments, the weight to volume ratio (g/ml) of compound 1 described in step A and the fourth organic solvent described in step D2 is 1:10, 1:15, 1:20, 1 :25, 1:30, 1:35, 1:40, 1:45 or 1:50; in other specific embodiments, compound 1 described in step A and step D2
  • the weight to volume ratio (g/ml) of the fourth organic solvent can also be other ratios within the range, such as 1:11, 1:12, 1:13, 1:14, 1:16, 1:17, 1:18, 1:19, 1:21...etc.
  • the first organic solvent, the second organic solvent, the third organic solvent, and the fourth organic solvent may be the following combinations:
  • the first organic solvent is acetonitrile
  • the second organic solvent is acetonitrile
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is n-hexane.
  • the first organic solvent is acetonitrile
  • the second organic solvent is acetonitrile
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is methane. Tert-butyl ether.
  • the first organic solvent is acetonitrile
  • the second organic solvent is acetonitrile
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane
  • the first organic solvent is acetonitrile
  • the second organic solvent is acetonitrile
  • the third organic solvent is methanol
  • the fourth organic solvent is methyl tert. Butyl ether.
  • the first organic solvent is acetonitrile
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol.
  • the first organic solvent is acetonitrile
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol.
  • the solvent is methyl tert-butyl ether.
  • the first organic solvent is acetonitrile
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is acetonitrile
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is methanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is acetonitrile
  • the second organic solvent is methanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is acetonitrile
  • the second organic solvent is methanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is acetonitrile
  • the second organic solvent is methanol
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane
  • the first organic solvent is acetonitrile
  • the second organic solvent is methanol
  • the third organic solvent is methanol
  • the fourth organic solvent is methyl tert. Butyl ether.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol. is n-hexane.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol. It is methyl tert-butyl ether.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is methanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol.
  • the organic solvent is n-hexane.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol.
  • the organic solvent is methyl tert-butyl ether.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is methanol
  • the fourth organic solvent It is methyl tert-butyl ether.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is methanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol. is n-hexane.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is methanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol. It is methyl tert-butyl ether.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is methanol
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is anhydrous ethanol
  • the second organic solvent is methanol
  • the third organic solvent is methanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is methanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is methanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is methanol
  • the second organic solvent is methanol
  • the organic solvent is acetonitrile
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane
  • the first organic solvent is methanol
  • the second organic solvent is acetonitrile
  • the third organic solvent is methanol
  • the fourth organic solvent is methyl tert. Butyl ether.
  • the first organic solvent is methanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol.
  • the first organic solvent is methanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is anhydrous ethanol. It is methyl tert-butyl ether.
  • the first organic solvent is methanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is methanol
  • the second organic solvent is anhydrous ethanol
  • the third organic solvent is methanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is methanol
  • the second organic solvent is methanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is n-hexane. alkyl.
  • the first organic solvent is methanol
  • the second organic solvent is methanol
  • the third organic solvent is anhydrous ethanol
  • the fourth organic solvent is methanol.
  • the first organic solvent is methanol
  • the second organic solvent is methanol
  • the third organic solvent is methanol
  • the fourth organic solvent is n-hexane
  • the first organic solvent is methanol
  • the second organic solvent is methanol
  • the third organic solvent is methanol
  • the fourth organic solvent is methyl tert. Butyl ether.
  • a non-limiting example of removing the amino protecting group R by the hydrochloric acid method described in step A is: dissolving compound 1 in an appropriate amount of organic solvent (such as dichloromethane, tetrahydrogen Furan, 2-methyltetrahydrofuran, etc.), then add HCl and organic solvents (such as ethyl acetate, ethanol, etc.) or water to prepare a hydrochloric acid solution at a certain concentration (the concentration of the hydrochloric acid solution can be 20% to 38%, such as 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36% , 37%, 38%, etc.), reaction at 10-30°C, where the weight to volume ratio (g/ml) of compound 1 and hydrochloric acid solution is 1:1 ⁇ 5 (such as 1:1, 1:2, 1:3, 1:4, 1:5 or other ratio within the range).
  • organic solvent such
  • the hydrochloric acid solution is a solution made of concentrated hydrochloric acid and ethanol; in other specific embodiments, the hydrochloric acid solution is a solution made of concentrated hydrochloric acid and water.
  • the concentration of the hydrochloric acid solution is 25%; in other specific embodiments, the concentration of the hydrochloric acid solution is 26%; in other specific embodiments, the concentration of the hydrochloric acid solution is 25%.
  • the concentration of the hydrochloric acid solution is 27%; in other specific embodiments, the concentration of the hydrochloric acid solution is 28%; in other specific embodiments, the concentration of the hydrochloric acid solution is 29%; in In other specific embodiments, the concentration of the hydrochloric acid solution is 30%; in other specific embodiments, the concentration of the hydrochloric acid solution is 31%; in other specific embodiments, the concentration of the hydrochloric acid solution is 30%.
  • the concentration of the hydrochloric acid solution is 32%; in other specific embodiments, the concentration of the hydrochloric acid solution is 33%; in other specific embodiments, the concentration of the hydrochloric acid solution is 34%; in In other specific embodiments, the concentration of the hydrochloric acid solution is 35%; in other specific embodiments, the concentration of the hydrochloric acid solution is 36%; in other specific embodiments, the concentration of the hydrochloric acid solution is 35%.
  • the concentration of the hydrochloric acid solution is 37%; in other specific embodiments, the concentration of the hydrochloric acid solution is 38%.
  • the weight-to-volume ratio (g/ml) of the compound 1 and the hydrochloric acid solution is 1:2; in other specific embodiments, the weight-to-volume ratio of the compound 1 to the hydrochloric acid solution is 1:2.
  • the ratio (g/ml) is 1:3; in some other specific embodiments, the weight-to-volume ratio (g/ml) of the compound 1 and the hydrochloric acid solution is 1:4; in some other specific embodiments , the weight-to-volume ratio (g/ml) of the compound 1 and hydrochloric acid solution is 1:5.
  • the step of removing the amino protecting group R by the hydrochloric acid method described in step A is to dissolve compound 1 in an appropriate amount of methylene chloride, add a hydrogen chloride ethanol solution with a concentration of 30%, 10-30 °C reaction, wherein the weight-to-volume ratio (g/ml) of compound 1 and hydrochloric acid solution is 1:3.
  • the step of removing the amino protecting group R by the hydrochloric acid method described in step A is to dissolve compound 1 in an appropriate amount of methylene chloride, add a 30% aqueous hydrogen chloride solution, 10-30 ° C reaction, wherein the weight to volume ratio of compound 1 and hydrochloric acid solution (g/ml) is 1:3.
  • the preparation and purification method of methyl auristatin E intermediate provided by the invention has fewer steps in the synthesis method, simple operation, cheap and easy-to-obtain raw materials with high safety, simple purification method, and extremely high purity of the purified product (can be Up to 91% or more), and the yield of the method provided by the invention can be as high as 95%.
  • organic solvents such as acetonitrile, absolute ethanol or methanol
  • Figure 1 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 1;
  • Figure 2 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 2;
  • Figure 3 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 3;
  • Figure 4 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 4;
  • Figure 5 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 5;
  • Figure 6 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 6;
  • Figure 7 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Example 7;
  • Figure 8 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Comparative Example 1;
  • Figure 9 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Comparative Example 2;
  • Figure 10 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Comparative Example 3;
  • Figure 11 is a chromatogram of the compound represented by formula (I) prepared by the preparation method of Comparative Example 4.
  • Compound 1-1 was used to remove the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are: add 500 mg of compound 1-1 and 1.5 ml of methylene chloride into a three-necked flask and stir until the solution is clear, then start adding 30 drops of % hydrogen chloride ethanol solution, 1.5 ml, control the reaction in the range of 10-30°C for 2 hours.
  • Compound 1-1 was removed from the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are as follows: add 800 mg of compound 1-1 and 4 ml of tetrahydrofuran to a three-necked flask and stir until the solution is clear, then start to dropwise add 25% hydrogen chloride ethanol solution 4ml, control the reaction at 20-25°C for 2 hours.
  • Compound 1-1 was used to remove the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are as follows: add 600 mg of compound 1-1 and 3 ml of dimethyltetrahydrofuran to a three-necked flask and stir until the solution is clear, then start adding 36% dropwise 2.4 ml of hydrogen chloride aqueous solution, control the reaction in the 15-20°C range for 3 hours.
  • Compound 1-1 was removed from the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are: add 10.0g of compound 1-1 and 60ml of methylene chloride into a three-necked flask and stir until the solution is clear, then start adding 25% dropwise 40 ml of hydrogen chloride methanol solution, react at 15-20°C for 3 hours.
  • Compound 1-1 was removed from the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are: add 500 mg of compound 1-1 and 2 ml of methylene chloride into a three-necked flask and stir until dissolved, then start adding 32% dropwise 1.5 ml of hydrogen chloride ethanol solution, control the reaction in the 10-20°C range for 3 hours.
  • Compound 1-1 was removed from the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are as follows: Add 1g of compound 1-1 and 4ml of tetrahydrofuran to a three-necked flask, stir until the solution is clear, and then start to add 27% hydrogen chloride ethanol dropwise. 4 ml of solution, control the reaction at 20-30°C for 2 hours.
  • Compound 1-1 was removed from the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are as follows: Add 2g of compound 1-1 and 4ml of tetrahydrofuran to a three-necked flask and stir until the solution is clear, then start to add 36% hydrogen chloride ethanol dropwise. 4 ml of solution, control the reaction in the range of 10-30°C for 2 hours.
  • the Boc protecting group of compound 1-1 was removed using the hydrochloric acid method.
  • the specific steps involved in this example are: add 100 mg of compound 1-1 and 0.5 ml of methylene chloride into a three-necked flask, stir until the solution is clear, and then open Begin to add 0.5 ml of 32% hydrogen chloride ethanol solution dropwise, and control the reaction in the 20-30°C range for 1 hour.
  • Compound 1-1 was used to remove the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are: add 1g of compound 1-1 and 6ml of methylene chloride to a three-necked flask and stir until the solution is clear, then start adding 27% hydrogen chloride dropwise. 4 ml of ethanol solution, react at 15-20°C for 3 hours.
  • Compound 1-1 was removed from the Boc protecting group using the hydrochloric acid method.
  • the specific steps involved in this example are: add 600 mg of compound 1-1 and 2.4 ml of methylene chloride into a three-necked flask and stir until the solution is clear, then start adding 30 drops of % hydrogen chloride ethanol solution 1.8ml, control the reaction in the range of 10-20°C for 3 hours.
  • the preparation and purification method of methyl auristatin E intermediate provided by the present invention has fewer steps in the synthesis method, is easy to operate, the raw materials are cheap and easy to obtain and have high safety, the purification method is simple, and the purified product is extremely pure. High, up to more than 91%, and the yield of the method provided by the invention can be as high as 95%.
  • organic solvents such as acetonitrile, absolute ethanol or methanol

Abstract

一种甲基奥瑞他汀E中间体的制备及纯化方法，该方法步骤少，操作简便，原料价廉易得且安全性高，纯化方法简单，纯化后产物纯度极高，并且该方法的收率可高达95％，不仅提高生产过程的安全性，更是十分显著的提高产品的收率，降低了后续生产成本，适于工业化推广。

Description

一种甲基奥瑞他汀E中间体的制备及纯化方法 技术领域
本发明涉及化合物合成方法领域，具体涉及一种甲基奥瑞他汀E化合物(即MMAE)中间体的制备及纯化方法。
背景技术
MMAE(Monomethyl Auristantin E，也称甲基奥瑞他汀E)，是一种奥瑞他汀类的全合成衍生物，其能通过抑制微管蛋白聚合而起到有效的有丝***抑制作用，目前已广泛用做细胞毒性成分(即药物部分)用来合成抗体药物偶联物(Antibody drug conjugate，简称ADC)以治疗癌症。
目前，MMAE较为通用的制备路线如下所示，其中步骤1中涉及的化合物b为制备MMAE过程中主要的中间体。
然而，目前现行的化合物b制备方法存在制备产品纯度低或是收率低或杂质残留数量较多等问题。如公开号为CN105968038A的中国专利公开了一种二肽类化合物盐酸盐(即化合物b)的制备方法，其路线为：
该专利在说明书第7页的实施例8中公开了这样一种制备及纯化方法：将化合物A采用盐酸法脱除Boc保护基后，依次加入甲基叔丁基醚、二氧六环、甲基叔丁基醚后，得到化合物b的粗品，之后再用四氢呋喃和 庚烷进行纯化，得到纯化后的化合物b，其纯度为99.6％，但是收率仅为82.3％。除此之外，该方法中涉及的二氧六环极易氧化，氧化后容易发生***，为安全生产带来很多危险因素。
发明内容
为了解决上述问题，本发明提供了一种新的甲基奥瑞他汀E中间体的制备及纯化方法，通过采用有机试剂减压浓缩除杂的方式制备得到了高纯低杂的甲基奥瑞他汀E中间体。
具体的，本发明制备的甲基奥瑞他汀E中间体的结构如式(I)所示(即上述化合物b，又称式(I)化合物，下同)：
所述的制备及纯化方法的制备路线为：
所述的R为氨基保护基团，所述的制备及纯化方法包括如下步骤：
A.将化合物1采用盐酸法脱除氨基保护基R；
B.待步骤A反应结束后，向步骤A的反应液中加入适量第一有机溶剂，减压浓缩，得浓缩物a；
C.向步骤B所得的浓缩物a中加入适量第二有机溶剂，减压浓缩，得浓缩物b；
D.对浓缩物b进一步进行纯化，
其中，可以理解的是，R可以是所有可以通过盐酸法脱除氨基保护的氨基保护基团。在一些优选的实施例中，所述的氨基保护基团R为Boc保护基、Cbz保护基、Tfa保护基、Tos保护基、Trt保护基、或DMB保护基，即所述的氨基保护基团R的结构可以非限制性的选自：
所述的第一有机溶剂选自乙腈、无水乙醇、甲醇；
所述的第二有机溶剂选自乙腈、无水乙醇、甲醇；
在一些具体的实施例中，所述的化合物1可以选自以下结构：
在一些更具体的实施例中，所述的化合物1的结构为：
在另一些更具体的实施例中，所述的化合物1的结构为：
在另一些更具体的实施例中，所述的化合物1的结构为：
在另一些更具体的实施例中，所述的化合物1的结构为：
在另一些具体的实施例中，所述的化合物1的结构为：
在另一些更具体的实施例中，所述的化合物1的结构为：
在一些优选的实施例中，所述的步骤D进一步包括步骤D1，所述的步骤D1包括：向步骤C中所得到的浓缩物b中加入适量第三有机溶剂，搅拌溶解，得溶解液c；所述的第三有机溶剂选自甲醇或无水乙醇。
在另一些优选的实施例中，所述的步骤D进一步包括步骤D2，所述步骤D2在所述步骤D1之后进行，所述步骤D2包括：向步骤D1所得到的溶解液c中加入适量第四有机溶剂，过滤，取滤饼，干燥后即为式(I)所示化合物；所述的第四有机溶剂选自正己烷或甲基叔丁基醚。
在一些优选的实施例中，步骤A中所述的化合物1和步骤B中所述的第一有机溶剂的重量体积比(g/ml)为1:4～15。在一些具体的实施例中，步骤A中所述的化合物1和步骤B中所述的第一有机溶剂的重量体积比 (g/ml)为1:4或1：5或1：6或1：7或1：8或1：9或1：10或1：11或1：12或1：13或1：14或1：15在一些具体的实施例中，步骤A中所述的化合物1和步骤B中所述的第一有机溶剂的重量体积比也可以是上述1:4～15范围中的其他比例。
在一些优选的实施例中，步骤B中所述的减压浓缩温度为20-40℃。在一些具体的实施例中，步骤B中所述的减压浓缩温度为20℃、21℃、22℃、23℃、24℃、25℃、26℃、27℃、28℃、29℃、30℃、31℃、32℃、33℃、34℃、35℃、36℃、37℃、38℃、39℃、或40℃；在另一些具体的实施例中，步骤B中所述的减压浓缩温度为20-40℃范围内的其他温度。
在一些优选的实施例中，步骤A中所述的化合物1和步骤C中所述的第二有机溶剂的重量体积比(g/ml)为1:4～15。在一些具体的实施例中，步骤A中所述的化合物1和步骤C中所述的第二有机溶剂的重量体积比(g/ml)为1:4、1:5、1:6、1:7、1:8、1:9、1:10、1:11、1:12、1:13、1:14或者1:15；在一些具体的实施例中，步骤A中所述的化合物1和步骤C中所述的第二有机溶剂的重量体积比也可以是上述所述范围中的其他比例。
在一些优选的实施例中，步骤C中所述的减压浓缩温度为20-40℃。在一些具体的实施例中，步骤C中所述的减压浓缩温度为20℃、21℃、22℃、23℃、24℃、25℃、26℃、27℃、28℃、29℃、30℃、31℃、32℃、33℃、34℃、35℃、36℃、37℃、38℃、39℃或者40℃；在一些具体的实施例中，步骤C中所述的减压浓缩温度还可以为20-40℃范围内的其他温度。
在一些优选的实施例中，步骤A中所述的化合物1和步骤D1中所述的第三有机溶剂的重量体积比(g/ml)为1:2～8。在一些具体的实施例中，步骤A中所述的化合物1和步骤D1中所述的第三有机溶剂的重量体积比(g/ml)为1：2、1：3、1：4、1：5、1：6、1：7或者1：8；在另一些具体的实施例中，步骤A中所述的化合物1和步骤D1中所述的第三有机溶剂的重量体积比可以是上述所述范围中的其他比例。
在一些优选的实施例中，步骤A中所述的化合物1和步骤D2中所述的第四有机溶剂的重量体积比(g/ml)为1:10～50。在一些具体的实施例中，步骤A中所述的化合物1和步骤D2中所述的第四有机溶剂的重量体积比(g/ml)为1:10、1:15、1:20、1:25、1:30、1:35、1:40、1:45或者1:50；在另一些具体的实施例中，步骤A中所述的化合物1和步骤D2中 所述的第四有机溶剂的重量体积比(g/ml)还可以为范围内的其他比例，如1:11、1:12、1:13、1:14、1:16、1:17、1:18、1:19、1:21......等。
在一些具体的实施例中，所述的第一有机溶剂、第二有机溶剂、第三有机溶剂、第四有机溶剂可以为如下的组合：

在一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为无水乙醇，所述的第四有机 溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为乙腈，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为无水乙醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二 有机溶剂为乙腈，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为乙腈，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为无水乙醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为无水乙醇，所述的第四有机溶剂为甲基叔丁基醚。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为正己烷。
在另一些具体的实施例中，所述的第一有机溶剂为甲醇，所述的第二有机溶剂为甲醇，所述的第三有机溶剂为甲醇，所述的第四有机溶剂为甲基叔丁基醚。
在一些优选的实施例中，步骤A中所述的盐酸法脱除氨基保护基R的非限制性示例为：将化合物1溶于适量有机溶剂中(如二氯甲烷、四氢 呋喃、2-甲基四氢呋喃等)，之后加入HCl和有机溶剂(如乙酸乙酯、乙醇等)或水以一定浓度配成的盐酸溶液(其中盐酸溶液的浓度可以为20％～38％，如20％、21％、22％、23％、24％、25％、26％、27％、28％、29％、30％、31％、32％、33％、34％、35％、36％、37％、38％等)，10-30℃反应，其中化合物1和盐酸溶液的重量体积比(g/ml)为1:1～5(如1:1、1:2、1:3、1:4、1:5或范围内的其他比例)。
在一些具体的实施例中，所述的盐酸溶液为由浓盐酸与乙醇配成的溶液；在另一些具体的实施例中，所述的盐酸溶液为由浓盐酸与水配成的溶液。
在一些具体的实施例中，所述的盐酸溶液的浓度为25％；在另一些具体的实施例中，所述的盐酸溶液的浓度为26％；在另一些具体的实施例中，所述的盐酸溶液的浓度为27％；在另一些具体的实施例中，所述的盐酸溶液的浓度为28％；在另一些具体的实施例中，所述的盐酸溶液的浓度为29％；在另一些具体的实施例中，所述的盐酸溶液的浓度为30％；在另一些具体的实施例中，所述的盐酸溶液的浓度为31％；在另一些具体的实施例中，所述的盐酸溶液的浓度为32％；在另一些具体的实施例中，所述的盐酸溶液的浓度为33％；在另一些具体的实施例中，所述的盐酸溶液的浓度为34％；在另一些具体的实施例中，所述的盐酸溶液的浓度为35％；在另一些具体的实施例中，所述的盐酸溶液的浓度为36％；在另一些具体的实施例中，所述的盐酸溶液的浓度为37％；在另一些具体的实施例中，所述的盐酸溶液的浓度为38％。
在一些具体的实施例中，所述的化合物1和盐酸溶液的重量体积比(g/ml)为1:2；在另一些具体的实施例中，所述的化合物1和盐酸溶液的重量体积比(g/ml)为1:3；在另一些具体的实施例中，所述的化合物1和盐酸溶液的重量体积比(g/ml)为1:4；在另一些具体的实施例中，所述的化合物1和盐酸溶液的重量体积比(g/ml)为1:5。
在一些更具体的实施例中，步骤A中所述的盐酸法脱除氨基保护基R的步骤为将化合物1溶于适量二氯甲烷中，加入浓度为30％的氯化氢乙醇溶液，10-30℃反应，其中所述的化合物1和盐酸溶液的重量体积比(g/ml)为1:3。
在另一些更具体的实施例中，步骤A中所述的盐酸法脱除氨基保护基R的步骤为将化合物1溶于适量二氯甲烷中，加入浓度为30％的氯化氢水溶液，10-30℃反应，其中所述的化合物1和盐酸溶液的重量体积比 (g/ml)为1:3。
本发明提供的甲基奥瑞他汀E中间体的制备及纯化方法，合成方法中的步骤少，操作简便，原料价廉易得且安全性高，纯化方法简单，纯化后产物纯度极高(可高达91％以上)，并且本发明提供的方法收率可高达95％，通过采用乙腈、无水乙醇或甲醇等有机溶剂减压带干反应产物，使得所制备产品中残留杂质种类大幅减少。不仅提高生产过程的安全性，更是十分显著的提高产品的收率及纯度，降低了后续生产成本，适于工业化生产。
附图说明
图1为通过实施例1制备方法制备的式(I)所示的化合物的色谱图；
图2为通过实施例2制备方法制备的式(I)所示的化合物的色谱图；
图3为通过实施例3制备方法制备的式(I)所示的化合物的色谱图；
图4为通过实施例4制备方法制备的式(I)所示的化合物的色谱图；
图5为通过实施例5制备方法制备的式(I)所示的化合物的色谱图；
图6为通过实施例6制备方法制备的式(I)所示的化合物的色谱图；
图7为通过实施例7制备方法制备的式(I)所示的化合物的色谱图；
图8为通过对照例1制备方法制备的式(I)所示的化合物的色谱图；
图9为通过对照例2制备方法制备的式(I)所示的化合物的色谱图；
图10为通过对照例3制备方法制备的式(I)所示的化合物的色谱图；
图11为通过对照例4制备方法制备的式(I)所示的化合物的色谱图。
具体实施方式
下面结合具体实施方式对本发明的技术方案作进一步非限制性的详细说明。需要指出的是，下述实施例仅为说明本发明的技术构思及特点，其目的在于让本领域技术人员能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。
实施例1
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：将向三口瓶中加入500mg化合物1-1和二氯甲烷1.5ml搅至溶清后，开始滴加30％氯化氢乙醇溶液1.5ml，控制在10-30℃区间反应2h。
之后向上述反应液中加入3ml乙腈搅匀后，转入单口瓶中，24-28℃水浴减压浓缩。
待浓缩完毕后，再次向单口瓶中加入5ml乙腈，摇匀后于24-28℃水浴继续减压浓缩至干。
将上步得到的浓缩产物中加入1.5ml无水乙醇搅拌溶解后缓慢滴加7.5ml甲基叔丁基醚，瓶内析出大量白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物403mg，收率为95％，纯度为99.79％，最大单杂为0.14％(见图1)。
实施例2
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：向三口瓶中加入800mg化合物1-1和4ml四氢呋喃搅至溶清后，开始滴加25％氯化氢乙醇溶液4ml，控制在20-25℃区间反应2h。
之后向上述反应液中加入6.4ml无水乙醇搅匀后转入单口瓶中，24-28℃水浴减压浓缩。
浓缩完毕后，再次向单口瓶中加入6.4ml无水乙醇摇匀后于24-28℃水浴继续减压浓缩至干。
将上步得到的浓缩产物中加入4ml无水乙醇搅拌溶解后缓慢滴加20ml甲基叔丁基醚，瓶内析出大量白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物642mg，收率为94.5％，纯度为99.53％，最大单杂为0.30％(见图2)。
实施例3
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：向三口瓶中加入600mg化合物1-1和3ml二甲基四氢呋喃搅至溶清后，开始滴加36％氯化氢水溶液2.4ml，控制在15-20℃区间反应3h。
向反应液中加入6ml甲醇搅匀后转入单口瓶，24-28℃水浴减压浓缩。
浓缩完毕后，再次向单口瓶中加入4.8ml乙腈摇匀后于24-28℃水浴继续减压浓缩至干。
将上步得到的浓缩产物中加入2.4ml甲醇搅拌溶解后缓慢滴加12ml正己烷，瓶内析出大量白色固体，抽滤取滤饼，30～35℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物475mg，收率为93.2％，纯度为99.43％，最大单杂为0.37％(见图3)。
实施例4
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：向三口瓶中加入10.0g化合物1-1和60ml二氯甲烷搅至溶清后，开始滴加25％氯化氢甲醇溶液40ml，15-20℃反应3h。
向反应液中加入100ml甲醇搅匀后转入单口瓶中，26℃水浴减压浓缩。
浓缩完毕后，向单口瓶中加入100ml甲醇摇匀后于26℃水浴继续减压浓缩至干。再重复加入相同体积甲醇减压蒸干一次。
将上步得到的浓缩产物中加入30ml甲醇搅拌溶解后缓慢滴加150ml正己烷，瓶内析出大量白色固体，抽滤取滤饼，30～35℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物8.0g，收率为94.2％，纯度为99.62％，单杂为0.13％(见图4)。
实施例5
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：将向三口瓶中加入500mg化合物1-1和二氯甲烷2ml搅至溶清后，开始滴加32％氯化氢乙醇溶液1.5ml，控制在10-20℃区间反应3h。
之后向上述反应液中加入2ml乙腈搅匀后，转入单口瓶中，24-28℃水浴减压浓缩。
待浓缩完毕后，再次向单口瓶中加入2ml乙腈，摇匀后于24-28℃水浴继续减压浓缩至干。
将上步得到的浓缩产物中加入1ml无水乙醇搅拌溶解后缓慢滴加5ml甲基叔丁基醚，瓶内析出大量白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物386mg，收率为91％，纯度为99.63％，最大单杂为0.16％(见图5)。
实施例6
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：将向三口瓶中加入1g化合物1-1和四氢呋喃4ml搅至溶清后，开始滴加27％氯化氢乙醇溶液4ml，控制在20-30℃区间反应2h。
之后向上述反应液中加入15ml乙腈搅匀后，转入单口瓶中，24-28℃水浴减压浓缩。
待浓缩完毕后，再次向单口瓶中加入15ml乙腈，摇匀后于24-28℃水浴继续减压浓缩至干。
将上步得到的浓缩产物中加入8ml无水乙醇搅拌溶解后缓慢滴加50ml甲基叔丁基醚，瓶内析出大量白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物789mg，收率为93％，纯度为99.53％，最大单杂为0.17％(见图6)。
实施例7
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：将向三口瓶中加入2g化合物1-1和四氢呋喃4ml搅至溶清后，开始滴加36％氯化氢乙醇溶液4ml，控制在10-30℃区间反应2h。
之后向上述反应液中加入14ml甲醇搅匀后，转入单口瓶中，24-28℃水浴减压浓缩。
待浓缩完毕后，再次向单口瓶中加入14ml甲醇，摇匀后于24-28℃水浴继续减压浓缩至干。
将上步得到的浓缩产物中加入8ml无水乙醇搅拌溶解后缓慢滴加20ml甲基叔丁基醚，瓶内析出大量白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物1561mg，收率为92％，纯度为99.32％，最大单杂为0.23％(见图7)。
对照例1
向三口瓶中加入5.0g化合物1-1和10ml二氯甲烷搅至溶清后，开始滴加25％氯化氢乙醇溶液20ml，15-20℃反应1h。
将反应液倒入0～5℃的80ml正己烷中搅拌，析出油状物。倒掉上清液，真空拉干至重量不再变化。即得式(I)所示的化合物3.81g，收率为89.8％，纯度为94.6％，最大单杂为1.40％(见图8)
对照例2
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：向三口瓶中加入100mg化合物1-1和二氯甲烷0.5ml搅至溶清后，开 始滴加32％氯化氢乙醇溶液0.5ml，控制在20-30℃区间反应1h。
之后向上述反应液中加入0.5ml乙腈搅匀后，转入单口瓶中，24-28℃水浴减压浓缩至干。
将上步得到的浓缩产物加入0.5ml无水乙醇搅拌溶解后缓慢滴加5ml甲基叔丁基醚，瓶内析出大量白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物71mg，收率为74％，纯度为99.54％，最大单杂为0.13％(见图9)。
对照例3
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：向三口瓶中加入1g化合物1-1和6ml二氯甲烷搅至溶清后，开始滴加27％氯化氢乙醇溶液4ml，15-20℃反应3h。
向反应液中加入10ml 1,4-二氧六环搅匀后转入单口瓶中，24-28℃水浴减压浓缩。
浓缩完毕后，向单口瓶中加入10ml 1,4-二氧六环摇匀后于24-28℃水浴继续减压浓缩至干。
向上步得到的浓缩产物中加入5ml甲醇搅拌溶解后缓慢滴加15ml甲基叔丁基醚，瓶内析出白色固体，析出固体较少，抽滤取滤饼，30～35℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物0.5g，收率为58.9％，纯度为99.57％，最大单杂为0.19％(见图10)。
对照例4
将化合物1-1采用盐酸法脱除Boc保护基，本实施例涉及的具体步骤为：将向三口瓶中加入600mg化合物1-1和二氯甲烷2.4ml搅至溶清后，开始滴加30％氯化氢乙醇溶液1.8ml，控制在10-20℃区间反应3h。
之后向上述反应液中加入3ml乙腈搅匀后，转入单口瓶中，24-28℃水 浴减压浓缩。
待浓缩完毕后，再次向单口瓶中加入3ml乙腈，摇匀后于24-28℃水浴继续减压浓缩至干。
向上步得到的浓缩产物中加入3ml二氯甲烷搅拌溶解后缓慢滴加6ml正庚烷，瓶内析出白色固体，抽滤取滤饼，20～30℃真空干燥不少于12h至重量不再变化，即得式(I)所示的化合物342mg，收率为67.1％，纯度为99.02％，最大单杂为0.35％(见图11)。
经对比，本发明提供的甲基奥瑞他汀E中间体的制备及纯化方法，合成方法中的步骤少，操作简便，原料价廉易得且安全性高，纯化方法简单，纯化后产物纯度极高，高达91％以上，并且本发明提供的方法收率可高达95％，通过采用乙腈、无水乙醇或甲醇等有机溶剂减压带干反应产物，使得所制备产品中残留杂质种类大幅减少。不仅提高了生产过程的安全性，更是十分显著的提高了产品的收率及纯度，降低了后续生产成本，适于工业化生产。
本发明已通过各个具体实施例作了举例说明。但是，本领域普通技术人员能够理解，本发明并不限于各个具体实施方式，普通技术人员在本发明的范围内可以作出各种改动或变型，并且在本说明书中各处提及的各个技术特征可以相互组合，而仍不背离本发明的精神和范围。这样的改动和 变型均在本发明的范围之内。

Claims (11)

  1. 一种甲基奥瑞他汀E中间体的制备及纯化方法，所述的甲基奥瑞他汀E中间体的结构如式(I)所示：
    所述的制备及纯化方法的制备路线为：
    所述的R为氨基保护基团，其特征在于，所述的制备及纯化方法包括如下步骤：
    A.将化合物1采用盐酸法脱除氨基保护基R；
    B.待步骤A反应结束后，向步骤A的反应液中加入适量第一有机溶剂，减压浓缩，得浓缩物a；
    C.向步骤B所得的浓缩物a中加入适量第二有机溶剂，减压浓缩，得浓缩物b；
    D.对浓缩物b进一步进行纯化。
    其中：
    所述的氨基保护基团R为Boc保护基、Cbz保护基、Tfa保护基、Tos保护基、Trt保护基、或DMB保护基；
    所述的第一有机溶剂选自乙腈、甲醇或无水乙醇；
    所述的第二有机溶剂选自乙腈、甲醇或无水乙醇。
  2. 根据权利要求1所述的制备及纯化方法，其特征在于，所述步骤D进一步包括步骤D1，所述的步骤D1包括：向步骤C中所得到的浓缩物b中加入适量第三有机溶剂，搅拌溶解，得溶解液c；所述的第三有机溶剂选自甲醇或无水乙醇。
  3. 根据权利要求2所述的制备及纯化方法，其特征在于，所述步骤C进一步包括步骤D2，所述步骤D2在所述步骤D1之后进行，所述步骤D2包括：向步骤D1所得到的溶解液c中加入适量第四有机溶剂，过滤， 取滤饼，干燥后即为式(I)所示化合物；所述的第四有机溶剂选自正己烷或甲基叔丁基醚。
  4. 根据权利要求1-3中任一项所述的制备及纯化方法，其特征在于，所述的化合物1选自如下结构：
  5. 根据权利要求1所述的制备及纯化方法，其特征在于，步骤A中所述的化合物1和步骤B中所述的第一有机溶剂的重量体积比(g/ml)为1:4～15。
  6. 根据权利要求1所述的制备及纯化方法，其特征在于，步骤B中所述的减压浓缩温度为20-40℃之间。
  7. 根据权利要求1所述的制备及纯化方法，其特征在于，步骤A中所述的化合物1和步骤C中所述的第二有机溶剂的重量体积比(g/ml)为 1:4～15。
  8. 根据权利要求1所述的制备及纯化方法，其特征在于，步骤C中所述的减压浓缩温度为20-40℃。
  9. 根据权利要求1所述的制备及纯化方法，其特征在于，步骤A中所述的化合物1和步骤D1中所述的第三有机溶剂的重量体积比(g/ml)为1:2～8。
  10. 根据权利要求1所述的制备及纯化方法，其特征在于，步骤A中所述的化合物1和步骤D2中所述的第四有机溶剂的重量体积比为(g/ml)为1:10～50。
  11. 乙腈、甲醇或无水乙醇在制备一种甲基奥瑞他汀E中间体中去除反应杂质的应用，所述的甲基奥瑞他汀E中间体的结构如式(I)所示：
    所述的制备路线为：
    所述的R为氨基保护基团，所述的去除反应杂质是指使用乙腈、无水乙醇或甲醇针对上述制备路线的产物进行减压浓缩从而去除反应产物中的杂质。
PCT/CN2023/086387 2022-04-08 2023-04-06 一种甲基奥瑞他汀e中间体的制备及纯化方法 WO2023193730A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202380013588.1A CN117980291A (zh) 2022-04-08 2023-04-06 一种甲基奥瑞他汀e中间体的制备及纯化方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210366476 2022-04-08
CN202210366476.1 2022-04-08

Publications (1)

Publication Number Publication Date
WO2023193730A1 true WO2023193730A1 (zh) 2023-10-12

Family

ID=88244087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/086387 WO2023193730A1 (zh) 2022-04-08 2023-04-06 一种甲基奥瑞他汀e中间体的制备及纯化方法

Country Status (3)

Country Link
CN (1) CN117980291A (zh)
TW (1) TW202340144A (zh)
WO (1) WO2023193730A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
CN104185477A (zh) * 2011-11-17 2014-12-03 辉瑞公司 细胞毒性肽及其抗体-药物缀合物
CN105968038A (zh) * 2016-05-09 2016-09-28 湖北华世通生物医药科技有限公司 二肽类化合物的盐酸盐及其制备方法
CN109200291A (zh) * 2018-10-24 2019-01-15 中国医学科学院医药生物技术研究所 一种靶向于egfr的抗体偶联药物及其制备方法和其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
CN104185477A (zh) * 2011-11-17 2014-12-03 辉瑞公司 细胞毒性肽及其抗体-药物缀合物
CN105968038A (zh) * 2016-05-09 2016-09-28 湖北华世通生物医药科技有限公司 二肽类化合物的盐酸盐及其制备方法
CN109200291A (zh) * 2018-10-24 2019-01-15 中国医学科学院医药生物技术研究所 一种靶向于egfr的抗体偶联药物及其制备方法和其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MADERNA, A. ET AL.: "Discovery of Cytotoxic Dolastatin 10 Analogues with N‑Terminal Modifications", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 28 November 2014 (2014-11-28), pages 10527 - 10543, XP055584456, DOI: 10.1021/jm501649k *

Also Published As

Publication number Publication date
TW202340144A (zh) 2023-10-16
CN117980291A (zh) 2024-05-03

Similar Documents

Publication Publication Date Title
EP3778621B1 (en) Peptide synthesis method
JP6460366B2 (ja) アミノ基を一つ有するポリエチレングリコールの精製方法
AU2019268215B2 (en) Process for preparing intermediate of antibody drug conjugate
CN108697770B (zh) 用于溶液相gap肽合成的***和方法
US20100168415A1 (en) Process for preparation of Caspofungin acetate
EP3239165B1 (en) Composition containing nitrogen heterocyclic hexapeptide precursor and preparation method and application thereof
CN102875649A (zh) 一种制备特拉匹韦及其中间体的方法及所述中间体
CN109400528B (zh) 一种可博美的合成方法
WO2023193730A1 (zh) 一种甲基奥瑞他汀e中间体的制备及纯化方法
CN112979763A (zh) 一种基于可溶性疏水载体抗菌肽Oreoch-2的液相合成方法
WO2020262259A1 (ja) ペプチド化合物の製造方法、保護基形成用試薬、及び、縮合多環化合物
WO2022206870A1 (en) Preparation and purification process of monomethyl auristain e compound
US9840534B2 (en) Process for the manufacture of cyclic undecapeptides
CN112300012A (zh) 制备2-甲氧基乙胺盐酸盐的方法
CN108690121B (zh) 一种奈米非肽液相制备方法
WO2019218381A1 (zh) 一种合成etelcalcetide的方法
WO2019029598A1 (zh) 一种制备左乙拉西坦的方法
CA2826086A1 (en) Process for preparation of caspofungin acetate and intermediates
CN117567566B (zh) 一种环六肽-9的液相合成工艺
JP2010529094A (ja) ポリソルベート８０中への溶媒中のドセタキセルの直接溶解
CN114901721A (zh) 纯化聚乙二醇化合物的方法
KR20230074004A (ko) 뉴클레오린에 특이적으로 결합하는 agm 펩타이드를 제조하는 방법
WO2023175526A1 (en) Process for preparation of azabicyclo [3.1.0] hexane intermediates
CN116120395A (zh) 一种奈玛特韦中间体的制备方法
CN111138375A (zh) 一种药物中间体的手性提纯方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23784293

Country of ref document: EP

Kind code of ref document: A1